RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BioMarin Pharmaceutical Stock

BioMarin Pharmaceutical Liabilities 2025

BioMarin Pharmaceutical Liabilities

1.33 B USD

Ticker

BMRN

ISIN

US09061G1013

WKN

924801

In 2025, BioMarin Pharmaceutical's total liabilities amounted to 1.33 B USD, a -29.58% difference from the 1.89 B USD total liabilities in the previous year.

BioMarin Pharmaceutical Aktienanalyse

What does BioMarin Pharmaceutical do?

Biomarin Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare genetic diseases. The company was founded in 1997 and is headquartered in San Rafael, California. BioMarin Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

BioMarin Pharmaceutical revenue by segment

  • 100 % Development & Commercialization of Innovative Therapies

Liabilities Details

Assessing BioMarin Pharmaceutical's Liabilities

BioMarin Pharmaceutical's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating BioMarin Pharmaceutical's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing BioMarin Pharmaceutical's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

BioMarin Pharmaceutical's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in BioMarin Pharmaceutical’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about BioMarin Pharmaceutical stock

What is the level of liabilities of BioMarin Pharmaceutical this year?

BioMarin Pharmaceutical has a debt balance of 1.33 B USD this year.

What were the liabilities of BioMarin Pharmaceutical compared to the previous year?

The liabilities of BioMarin Pharmaceutical have increased by -29.58% dropped compared to the previous year.

What are the consequences of high debt for investors of BioMarin Pharmaceutical?

High liabilities can pose a risk for investors of BioMarin Pharmaceutical, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in BioMarin Pharmaceutical?

Low liabilities mean that BioMarin Pharmaceutical has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of BioMarin Pharmaceutical affect the company?

An increase in liabilities of BioMarin Pharmaceutical can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of BioMarin Pharmaceutical affect the company?

A decrease in the liabilities of BioMarin Pharmaceutical can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of BioMarin Pharmaceutical?

Some factors that can influence the liabilities of BioMarin Pharmaceutical include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of BioMarin Pharmaceutical so important for investors?

The liabilities of BioMarin Pharmaceutical are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can BioMarin Pharmaceutical take to modify the liabilities?

To change its liabilities, BioMarin Pharmaceutical can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does BioMarin Pharmaceutical pay?

Over the past 12 months, BioMarin Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioMarin Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of BioMarin Pharmaceutical?

The current dividend yield of BioMarin Pharmaceutical is .

When does BioMarin Pharmaceutical pay dividends?

BioMarin Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioMarin Pharmaceutical?

BioMarin Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of BioMarin Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioMarin Pharmaceutical located?

BioMarin Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von BioMarin Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioMarin Pharmaceutical from 7/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/7/2025.

When did BioMarin Pharmaceutical pay the last dividend?

The last dividend was paid out on 7/7/2025.

What was the dividend of BioMarin Pharmaceutical in the year 2024?

In the year 2024, BioMarin Pharmaceutical distributed 0 USD as dividends.

In which currency does BioMarin Pharmaceutical pay out the dividend?

The dividends of BioMarin Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The BioMarin Pharmaceutical stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von BioMarin Pharmaceutical

Our stock analysis for BioMarin Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioMarin Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.